Tuberculosis and COVID 19 Coinfection

The ongoing pandemic of novel corona-virus disease 2019 (COVID-19) has received worldwide attention by becoming a major global health threat. The tuberculosis and SARS-COV2 co-infection has not been frequently reported. The purpose of this work is to establish a focus on Tuberculosis and SARS-COV2 co-infection, to study the impact of HIV infection on the occurrence of COVID-19, and evaluate the place of BCG vaccination in reducing the morbidity and mortality linked to Covid-19. We reported three cases of co-infection tuberculosis and covid 19, in one case an HIV infection was noticed. The tuberculosis was pleural in the first case, multifocal in the second case and a miliary in the third case. The treatment consisted of antibacillaries, azithromycin and hydroxychloroquine with a favorable evolution. through published studies, we noticed that persons with active or latent TB have increased susceptibility for SARS-CoV–2 infection associated with rapid progression and severe involvement. Patients with severe immune-deficiencies, may be at risk for a severe course of COVID-19 disease. Regarding efficiency of BCG vaccination, limited data are available and does not confirm the existence of a protective effect of BCG against COVID-19.